Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Angle Plc ADR
(OP:
ANPCY
)
1.560
UNCHANGED
Streaming Delayed Price
Updated: 3:54 PM EDT, Aug 22, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Angle Plc ADR
< Previous
1
2
3
4
5
Next >
Angle PLC Announces Positive Headline Results From Ovarian Study
September 29, 2022
Via
ACCESSWIRE
Angle PLC announces Study using Parsortix in head and neck cancer
September 28, 2022
Via
ACCESSWIRE
Angle PLC Announces New Poster Presented at ASCP Meeting
September 13, 2022
Via
ACCESSWIRE
Angle PLC Announces Novel Assay; Predicts Malignancy in Pelvic Mass
September 12, 2022
Via
ACCESSWIRE
Angle PLC Announces Notice of Interim Results and Webcast
September 01, 2022
Via
ACCESSWIRE
Angle PLC Announces Issue of Equity
July 08, 2022
Exercise of Options and Total Voting Rights
From
ANGLE plc
Via
AccessWire
Angle PLC Announces Result of 2022 Annual General Meeting
June 29, 2022
GUILDFORD, SURREY / ACCESSWIRE / June 29, 2022 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company, announces that at the Annual General Meeting of the Company held earlier today,...
From
ANGLE plc
Via
AccessWire
Angle PLC Announces Spread of Breast Cancer Accelerates During Sleep
June 27, 2022
BREAKTHROUGH RESEARCH WITH PARSORTIX REVEALS SPREAD OF BREAST CANCER ACCELERATES DURING SLEEP
From
ANGLE plc
Via
AccessWire
Angle PLC Announces Issue of Equity
June 23, 2022
Exercise of Options and Total Voting Rights
From
ANGLE plc
Via
AccessWire
Angle PLC Announces Secured Contract From Pharma Services Customer
June 22, 2022
Additional contract for a new clinical trial
From
ANGLE plc
Via
AccessWire
Angle PLC Announces Predicting Immunotherapy Response in SCLC
June 16, 2022
PARSORTIX SYSTEM DEMONSTRATES POTENTIAL IN PREDICTING IMMUNOTHERAPY RESPONSE IN SMALL CELL LUNG CANCER
From
ANGLE plc
Via
AccessWire
Angle PLC Announces Potential Role of Invasive Cellular Protrusions
June 14, 2022
Prostate cancer cells may use invasive cellular protrusions to aid entry into the blood stream, a potential target in the metastatic process for novel therapy development
From
ANGLE plc
Via
AccessWire
Angle PLC Announces Partnership with Major United States Urology Group
May 30, 2022
PARTNERSHIP ESTABLISHED WITH A MAJOR UNITED STATES UROLOGY GROUP TO CONDUCT CLINICAL STUDIES IN PROSTATE CANCER AND AS A POTENTIAL ROUTE TO MARKET
From
ANGLE plc
Via
AccessWire
Angle PLC Announces Molecular Characterisation of CTCs
May 27, 2022
Parsortix system harvests intact CTCs for single-cell whole genomic sequencing from frozen and fresh blood samples with the same efficiency
From
ANGLE plc
Via
AccessWire
ANGLE receives FDA clearance for Parsortix
May 25, 2022
ANGLE ACHIEVES WORLD FIRST WITH FDA CLEARANCE FOR ITS PARSORTIX SYSTEMFDA De Novo product clearance to harvest cancer cells from blood for subsequent analysis offers the prospect of a new era of...
From
ANGLE plc
Via
AccessWire
Exposures
Product Safety
Angle PLC - Prostate Cancer UK Funds New Study Using Parsortix
May 20, 2022
Research Into the Use of Parsortix-Based CTC Blood Test To Assess Whether Prostate Cancer Patients Require Prostatectomy SurgeryPotential for a New Standard of Care in an Area of High Unmet Medical...
From
ANGLE plc
Via
AccessWire
Angle PLC Announces Preliminary Results
April 28, 2022
Our newswire features a comprehensive, flat-fee Press Release service. Generate quality engagement with real-time analytics to improve visibility and expand your influence.
From
ANGLE plc
Via
AccessWire
Exposures
Product Safety
Angle PLC Announces Notice of Preliminary Results and Webcast
April 20, 2022
GUILDFORD, UK / ACCESSWIRE / April 20, 2022 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company, will be releasing its preliminary results for the year ended 31 December 2021 on...
From
ANGLE plc
Via
AccessWire
Angle PLC Announces Poster on Parsortix System Presented at AACR 2022
April 14, 2022
PARSORTIX SYSTEM RESULTS PUBLISHED AS A POSTER AT LEADING CANCER CONFERENCE AACR 2022 Poster demonstrated use of Parsortix workflow for triple negative breast cancer GUILDFORD, UK / ACCESSWIRE / April...
From
ANGLE plc
Via
AccessWire
Angle PLC Announces Identifying Drug Targets in Cancer Metastasis
April 01, 2022
PARSORTIX SYSTEM DEMONSTRATES ABILITY TO ISOLATE CTCs FOR DOWNSTREAM MOLECULAR ANALYSIS, IDENTIFYING KEY DRUG TARGETS INVOLVED IN CANCER METASTASIS - World-class research identifies specific genetic...
From
ANGLE plc
Via
AccessWire
Angle PLC Announces Rapid Information on Patient Response to Therapies
March 29, 2022
PARSORTIX SYSTEM SHOWS POTENTIAL FOR PROVIDING RAPID INFORMATION ON PATIENT RESPONSE TO THERAPIES TARGETING METASTASIS - Existing chemotherapies, such as vinorelbine, may selectively target and reduce...
From
ANGLE plc
Via
AccessWire
Angle PLC Announces Identifying Therapeutic Targets in TNBC Patients
March 25, 2022
PARSORTIX SHOWS POTENTIAL FOR IDENTIFYING THERAPEUTIC TARGETS IN PATIENTS WITH TRIPLE NEGATIVE BREAST CANCER - Parsortix system harvests intact CTCs for whole genome sequencing identifying multiple...
From
ANGLE plc
Via
AccessWire
Angle PLC Announces Update on Laboratory Accreditation
March 15, 2022
ANGLE's US clinical laboratory issued Certificate of Registration, a key step to achieving CLIA accreditation GUILDFORD, UK / ACCESSWIRE / March 15, 2022 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a...
From
ANGLE plc
Via
AccessWire
Angle PLC Announces Holding(s) in Company
March 02, 2022
GUILDFORD, SURREY / ACCESSWIRE / March 2, 2022 / ANGLE plc (OTCQX:ANPCY )(AIM:AGL) TR-1: Standard form for notification of major holdings 1. Issuer Details ISIN GB0034330679 Issuer Name ANGLE plc UK or...
From
ANGLE plc
Via
AccessWire
Angle PLC Announces Issue of Equity
February 18, 2022
Exercise of Options and Total Voting Rights GUILDFORD, SURREY / ACCESSWIRE / February 18, 2022 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company, announces that following the...
From
ANGLE plc
Via
AccessWire
Angle PLC Announces Potential in Immunotherapy Treatment Selection
January 21, 2022
PEER-REVIEWED PUBLICATION HIGHLIGHTS POTENTIAL FOR PARSORTIX SYSTEM IN IMMUNOTHERAPY TREATMENT SELECTION Parsortix isolation of CTCs highlights relationship between PD-L1 expression and epithelial to...
From
ANGLE plc
Via
AccessWire
Angle PLC Announces Concordance of Parsortix with tissue biopsy
January 17, 2022
BREAKTHROUGH STUDY DEMONSTRATES FOR THE FIRST TIME CONCORDANCE OF PARSORTIX LIQUID BIOPSY BLOOD TEST WITH INVASIVE TISSUE BIOPSY OF THE METASTATIC SITE Study explores key unmet medical need for...
From
ANGLE plc
Via
AccessWire
Angle PLC Announces Update on Lab Accreditation and Ovarian Study
January 13, 2022
First submissions made in relation to accreditation of ANGLE clinical laboratories Ovarian cancer study sample analysis slower than planned GUILDFORD, SURREY / ACCESSWIRE / January 13, 2022 / ANGLE plc...
From
ANGLE plc
Via
AccessWire
Angle PLC Announces Insight into Drug Resistance in NSCLC
January 10, 2022
EPIGENETIC ALTERATIONS IN GENES FROM LIQUID BIOPSIES PROVIDE INSIGHT INTO DRUG RESISTANCE IN NON-SMALL LUNG CANCER PATIENTS Longitudinal analysis of paired samples of CTCs and ctDNA shows important...
From
ANGLE plc
Via
AccessWire
Angle PLC Announces Issue of Equity
December 22, 2021
Exercise of Options and Total Voting Rights GUILDFORD, SURREY / ACCESSWIRE / December 22, 2021 /ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company, announces that following the...
From
ANGLE plc
Via
AccessWire
< Previous
1
2
3
4
5
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.